Q-omics provides the consensus-scored NUP62CL profile across patient tissues and cancer cell-line models. NUP62CL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NUP62CL is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, NUP62CL RNA expression shows 18,445 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight LUAD, COAD, and KIRP as cancer lineages where NUP62CL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP62CL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP62CL survival associations across molecular data types. NUP62CL RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP62CL RNA expression–survival associations across cancer types. High NUP62CL expression shows unfavorable associations in LUAD, LGG, THCA and KICH, but favorable associations in CESC and KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for NUP62CL RNA expression.
This table summarizes NUP62CL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NUP62CL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP62CL shows lower tumor expression in KIRC and THCA and higher tumor expression in COAD, BLCA, LUAD and HNSC. The COAD box plot shows higher NUP62CL RNA expression in tumor versus normal tissue (log2 FC = +1.336, t-test p < 0.001).
This table shows molecular features associated with NUP62CL in patient tissues and cancer cell lines. In patient samples, NUP62CL shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, NUP62CL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BONE.
